Monday, 2 October, 2017

FierceBiotech Executive Summit: London

Royal Society of Medicine | London

About

Join FierceBiotech for our third annual Executive Summit in London. We’re hosting a half-day event at the Royal Society of Medicine where we’ll gather the experts together to discuss innovation around R&D in the UK. We’ll be looking ahead to see what’s in store for 2018 with leaders in the field discussing trends in the industry and then we’ll round out the day with a networking cocktail hour.

Speakers

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

Dr. John Beadle

CEO | Psioxus Therapeutics Ltd
John is Chief Executive Officer of Psioxus Therapeutics Ltd. a privately company developing immuno-oncology therapeutics. Headquartered in Oxford, UK, PsiOxus is focused upon developing a pipeline of oncolytic viruses for the treatment of solid tumors.

John was previously Co-founder and Chief Medical Officer of PowderMed Ltd., a privatel Oxford, UK biotech company, which he helped to build and lead before a successful trade sale in 2007 to Pfizer. He then became Entrepreneur in Residence at Imperial College London and has held the role of CEO in a number of start-up and early stage biotech companies. He was CEO of both Myotec Therapeutics and Hybrid Biosytems, before merging the two companies in 2011 to form PsiOxus Therapeutics.

In his early career, John held Research and Development roles of ascending seniority within The Wellcome Foundation, GlaxoWellcome and GlaxoSmithkline, where he was most recently the Vice President of Global Medical Operations. He was then Vice President of Product Development at the vaccines company PowderJect.

John graduated as a Medical Doctor at the University of Witwatersrand and received his Masters of Business Administration from the London Business School.

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

Christian Dillon

Senior Group Leader | Cancer Research UK’s Therapeutic Discovery Laboratories
Since joining CRUK-TDL (then CRT-DL) in 2005, Christian has led a broad range of projects from early target identification and validation through to lead optimisation. A cell biologist by training, Christian has experience in leading cross-functional project teams and has overseen a multi-project alliance on the DNA Damage Response with Teva Pharmaceuticals and currently leads an immune-oncology alliance with LifeArc. Christian has a strong interest in reducing novel target attrition rates within early stage drug discovery. Christian obtained his first degree in Biology from Imperial College, received his PhD from University College London in 2002 and went on to complete his postdoctoral research at the Medical Research Council Laboratory for Molecular Cell Biology.

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

Jon Edwards

Principal | Medicxi
Jon is a Principal in the Medicxi investment team with main focus on early-stage opportunities. Prior to Medicxi, Jon worked at Index as an Associate for two years. Before that, he worked as a life science strategy consultant at ClearView Healthcare Partners. He is on the boards of Palladio Biosciences and Z-Factor and is an observer on the board of Capella Bioscience and Apcintex.

Jon obtained his PhD in biochemistry and biophysics from UNC Chapel Hill and also conducted postdoctoral research at MIT, where he is an affiliate in the department of biological engineering.

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

John Haurum

CEO | F-star
John has over 15 years’ experience in building and leading biotech companies across discovery, development, financing and business development. He successfully managed several monoclonal, oligoclonal, and bispecific antibody products into clinical development, as well as managed and developed numerous collaborations with biopharmaceutical companies in the US, Europe, and Japan. Prior to joining F-star, John was VP Research, Biologics Products at ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company. Previously, he was a cofounder and Chief Scientific Officer of Symphogen A/S, a Danish biotechnology company developing therapeutic antibody combinations. John holds an MD from University of Aarhus, Denmark and a D.Phil. in Immunology from the Institute of Molecular Medicine, University of Oxford, UK.

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

Peter Pack

CEO | Crescendo Biologics
Peter Pack has 24 years of experience in the successful establishment and growth of international life science companies. For 16 years, he was CEO and Managing Director of product-oriented companies ranging from early stage up to international commercialization and profitability with several thousand certified products; predominantly working in Germany, the UK and Poland. He raised over € 54 m in venture capital, worked on several Boards and headed companies with up to 400 employees.

He started his career in the initial team of MorphoSys AG (1993-1999) as co-inventor of the commercially most successful phage library and was co-founder and CEO of the cancer diagnostics company mtm laboratories (1999-2008). The companies for which Peter worked in central positions were either successfully sold (mtm laboratories, Polytech Ophthalmologie, Signature Diagnostics), highly profitable (LGC Standards, Polytech) and/or went public (MorphoSys AG).

Mene Pangalos

Executive Vice-President | AstraZeneca’s Innovative Medicines and Early Development Biotech Unit
A member of the company’s Senior Executive team, Mene has overall responsibility for the company’s pharmaceutical discovery research and early development activities.

Since joining AstraZeneca in 2010, Mene has been instrumental in rebuilding the company’s commitment to science and scientific excellence. He has led the transformation of R&D productivity; driven deeper collaborations with academic, biotech and peer organisations; pioneered programmes to promote Open Innovation and fostered a science driven culture that rewards great science and truth-seeking behaviours.

Mene retains an active interest in neurodegenerative disease and neuropharmacology and continues to mentor post docs and PhD students.

Mene has published more than 140 peer-reviewed articles in scientific journals and is an internationally renowned expert in neuroscience and drug discovery. He is a leading figure in UK science, serving on several Boards including the Medical Research Council, the National Centre for Universities and Business Council, the Ministers and Industry Strategy Group and the Cambridge Biomedical Campus Strategy Board.

Mene is also overseeing the creation of AstraZeneca’s new £330 million research centre in Cambridge – a state of the art facility designed to stimulate collaborative scientific innovation and which will play an important role in the future success of the UK life science industry.

Edward Rayner

Investment Director | Arix Bioscience

Ben Adams

Editor | FierceBiotech (Moderator)
Ben Adams is a business, science and healthcare journalist who has worked as an editor for the UK publication Pharmafocus and as a group editor Pharmaceutical Marketing Europe, as well as a features and news writer for the BMJ and the Pharmaceutical Journal. He has an especial interest in market access, drug pricing and the ethics of the life sciences industry and has been heavily involved in ensuring the need for greater clinical study transparency remains on the agenda for the industry. On the personal side, he enjoys reading esoteric pieces of literary fiction from Charles Williams, Will Self, Ros Barber and Milan Kundera, and is currently awaiting the publication of his own set of literary juvenilia, coming to a second-hand bookshop no-where near anyone soon. Ben is based on the south coast of England and can be reached at [email protected]

Carly Helfand

Senior Editor | FiercePharma (Moderator)
Carly Helfand is a news editor with FierceMarkets' Life Sciences group, writing for FierceVaccines, FiercePharma and FiercePharmaMarketing. Carly got her start covering pharma while earning her master's at Northwestern University's Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post's Wonkblog and Cape Town's Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle. You can contact her at [email protected]

Tracy Staton

Editor-in-Chief | FierceBiotech & FiercePharma (Moderator)
Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for 8 years. Before that, she served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont and can be reached at [email protected], or find her on LinkedIn.

schedule

13:00 - 13:45: Registration and Networking

13:45 - 14:00: Introduction and Opening Remarks

14:00 - 15:00: Panel One: The immuno-oncology explosion

15:00 - 15:20: Coffee Break

15:20 - 16:10: Fireside Chat

16:10 - 16:30: Coffee Break

16:30 - 17:30: Panel Two: UK Venture Capital: Where’s the money going and who’s next

17:30 - 18:30: Reception and Networking

Agenda

The immuno-oncology explosion
Monday, 2 October, 2017| 14:00 - 15:00
Oncology today accounts for the largest share of R&D investment and represents the biggest market in the coming years. We will discuss the latest data in the field and how it changes—or doesn’t change—the outlook for other potential combination therapies and pipeline projects. With hundreds upon hundreds of combinations in testing, how can particular cocktails stand out, and how do gene therapies fit into this rapidly developing field.

Speakers

FirstName LastName

Job Title

FirstName LastName

Job Title

Dr. John Beadle

CEO | Psioxus Therapeutics Ltd

FirstName LastName

Job Title

FirstName LastName

Job Title

Christian Dillon

Senior Group Leader | Cancer Research UK’s Therapeutic Discovery Laboratories

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

John Haurum

CEO | F-star

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

Carly Helfand

Senior Editor | FiercePharma (Moderator)

FirstName LastName

Job Title
Fireside Chat
Monday, 2 October, 2017 | 15:20 - 16:10
How are biotech and pharma R&D execs in the U.K. taking advantage of local resources and combining with the global drug development industry in finding the most efficient path to a regulatory filing in the hottest areas of drug development, like gene therapies, rare disease treatments and immuno-oncology?

Speakers

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

Mene Pangalos

Executive Vice-President | AstraZeneca’s Innovative Medicines and Early Development Biotech Unit

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

Ben Adams

Editor | FierceBiotech (Moderator)
UK Venture Capital: Where’s the money going and who’s next
Monday, 2 October, 2017 |16:30 - 17:30

For biotech companies, funding is job one, and venture capital firms have to be on the leading edge of life sciences, which these days also means digital and data technology, too. Things are looking up: Investments through early raises in young biotechs have reached major levels in recent months.

The rebound doesn’t appear to just be based on a more positive economic outlook, but a belief in some genuinely exciting science, from gene therapy and gene editing, to RNAi and detecting cancer earlier than ever before. Are we seeing a genuine blooming of biomedical innovation, and is biotech, notably young biotech, “cool” again for money sources in the UK? Which therapeutic areas are hot and which are not? What new frontiers—digital and data included—are VCs most excited about?

Speakers

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

Jon Edwards

Principal | Medicxi

FirstName LastName

Job Title

Peter Pack

CEO | Crescendo Biologics

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

Edward Rayner

Investment Director | Arix Bioscience

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

Ben Adams

Editor | FierceBiotech (Moderator)

FirstName LastName

Job Title

Pricing

Standard Registration

£185 per person (Approximately $250)
*Please note that the fees to attend this event will be charged in US Dollars. The amount is approximately equivalent to £185 dependent upon the currency exchange rate at the time of registration.

location

FAQ

There is not a dedicated parking lot for the Royal Society of Medicine, and street parking is very limited. It is suggested that attendees arrive via public transportation or taxi. 

Yes, light refreshments will be served in the afternoon. Attendees are also invited to stay after the presentations for a cocktail reception.

Yes, WIFI is available.